Radioiodine in the management of benign thyroid disease -Guidelines royal college of physicians
Radioiodine in the management of benign thyroid disease
link to RCP website
These guidelines update those first published by the Royal College of Physicians in 1995.
Hyperthyroidism affects more than one in 200 people. While the original guidelines were influential in standardising treatment of the condition within the UK, these guidelines set out the latest recommendations for its management. Their scope has been widened to include the use of radioiodine to treat sporadic goitre; this treatment is now becoming established as a useful alternative to surgery for this condition.
The guidelines also cover recent changes in legislation relating to radioiodine administration and the effect of radioiodine on thyroid eye disease.
As well as specialists directly involved in the management of patients with hyperthyroidsim or goitre, the guidelines will be of interest to general physicians and general practitioners who are frequently involved with the follow-up for patients with this prevalent condition.
Overview of radioiodine therapy
Administration of radioiodine
Management of the first year following radioiodine therapy for thyrotoxicosis
Monitoring and follow-up after the first year
Information for patients
Sample consent form
Sample patient information card
Elements of a system to support long-term follow-up of patients treated with radioiodine